To summarize, our study demonstrated that tumor IDO1 expression was most likely to be affected by chemotherapy, because it increased significantly after NCT and no significant change was observed after NCRT in ESCC patients, and the increased tumor IDO1 expression after neoadjuvant therapy was associated with poor pathological response and prognosis. Here, IDO1 is linked to esophageal squamous cell carcinoma.